125 related articles for article (PubMed ID: 38659247)
1. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
Lucocq J; Hawkyard J; Haugk B; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; Van Laarhoven S; Robertson F; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Søreide K; Pandanaboyana S
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38659247
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Surgery; 2020 Dec; 168(6):994-1002. PubMed ID: 32139141
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
[TBL] [Abstract][Full Text] [Related]
5. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
Turrini O; Waters JA; Schnelldorfer T; Lillemoe KD; Yiannoutsos CT; Farnell MB; Sarr MG; Schmidt CM
HPB (Oxford); 2010 Sep; 12(7):447-55. PubMed ID: 20815853
[TBL] [Abstract][Full Text] [Related]
6. Predictors, Patterns, and Timing of Recurrence Provide Insight into the Disease Biology of Invasive Carcinomas Arising in Association with Intraductal Papillary Mucinous Neoplasms.
Habib JR; Kinny-Köster B; Amini N; Shoucair S; Cameron JL; Thompson ED; Fishman EK; Hruban RH; Javed AA; He J; Wolfgang CL
J Gastrointest Surg; 2022 Nov; 26(11):2311-2320. PubMed ID: 35915375
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
Swartz MJ; Hsu CC; Pawlik TM; Winter J; Hruban RH; Guler M; Schulick RD; Cameron JL; Laheru DA; Wolfgang CL; Herman JM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):839-44. PubMed ID: 19647950
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
Caponi S; Vasile E; Funel N; De Lio N; Campani D; Ginocchi L; Lucchesi M; Caparello C; Lencioni M; Cappelli C; Costa F; Pollina L; Ricci S; Mosca F; Falcone A; Boggi U
Eur J Surg Oncol; 2013 Apr; 39(4):396-403. PubMed ID: 23290583
[TBL] [Abstract][Full Text] [Related]
9. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
10. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.
Chari ST; Yadav D; Smyrk TC; DiMagno EP; Miller LJ; Raimondo M; Clain JE; Norton IA; Pearson RK; Petersen BT; Wiersema MJ; Farnell MB; Sarr MG
Gastroenterology; 2002 Nov; 123(5):1500-7. PubMed ID: 12404225
[TBL] [Abstract][Full Text] [Related]
11. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas.
Hirono S; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
Surgery; 2016 Aug; 160(2):306-17. PubMed ID: 27236360
[TBL] [Abstract][Full Text] [Related]
12. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
13. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
15. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
[TBL] [Abstract][Full Text] [Related]
16. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
[TBL] [Abstract][Full Text] [Related]
17. Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma.
Furukawa T; Takamatsu M; Inoue Y; Okamoto T; Mie T; Yamada Y; Takeda T; Kasuga A; Matsuyama M; Sasaki T; Ozaka M; Oba A; Ito H; Ono Y; Sato T; Takahashi YU; Saiura A; Sasahira N
Anticancer Res; 2022 May; 42(5):2645-2655. PubMed ID: 35489761
[TBL] [Abstract][Full Text] [Related]
18. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
[TBL] [Abstract][Full Text] [Related]
20. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.
Wasif N; Bentrem DJ; Farrell JJ; Ko CY; Hines OJ; Reber HA; Tomlinson JS
Cancer; 2010 Jul; 116(14):3369-77. PubMed ID: 20564064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
